Literature DB >> 30560924

Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors.

Zhuo Cheng1, Zhiying He2, Yongchao Cai2, Cheng Zhang1, Gongbo Fu1, Hengyu Li1, Wen Sun1, Changcheng Liu2, Xiuliang Cui1, Beifang Ning3, Daimin Xiang1, Tengfei Zhou1, Xiaofeng Li1, Weifen Xie3, Hongyang Wang4,5, Jin Ding6,7.   

Abstract

Normal cells become cancer cells after a malignant transformation, but whether cancer cells can be reversed to normal status remains elusive. Here, we report that the combination of hepatocyte nuclear factor 1A (HNF1A), HNF4A and forkhead box protein A3 (FOXA3) synergistically reprograms hepatocellular carcinoma (HCC) cells to hepatocyte-like cells (reprogrammed hepatocytes, rHeps). Our results show that rHeps lose the malignant phenotypes of cancer cells and retrieve hepatocyte-specific characteristics including hepatocyte-like morphology; global expression pattern of genes and specific biomarkers of hepatocytes; and the unique hepatic functions of albumin (ALB) secretion, glycogen synthesis, low-density lipoprotein (LDL) uptake, urea production, cytochrome P450 enzymes induction and drug metabolism. Intratumoral injection of these three factors efficiently shrank patient-derived tumor xenografts and reprogrammed HCC cells in vivo. Most importantly, transplantation of rHeps in the liver of fumarylacetoacetate hydrolase-deficient (Fah-/-) mice led to the reconstruction of hepatic lobules and the restoration of hepatic function. Mechanistically, exogenous expression of HNF1A, HNF4A and FOXA3 in HCC cells initiated the endogenous expression of numerous hepatocyte nuclear factors, which promoted the conversion of HCC cells to hepatocyte-like cells. Collectively, our results indicate the successful conversion of hepatoma cells to hepatocyte-like cells, not only extending our current knowledge of cell reprogramming but also providing a route towards a novel therapeutic strategy for cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30560924      PMCID: PMC6355772          DOI: 10.1038/s41422-018-0111-x

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  33 in total

1.  PU.1 and C/EBPalpha/beta convert fibroblasts into macrophage-like cells.

Authors:  Ru Feng; Sabrina C Desbordes; Huafeng Xie; Ester Sanchez Tillo; Fiona Pixley; E Richard Stanley; Thomas Graf
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-18       Impact factor: 11.205

Review 2.  Organogenesis and development of the liver.

Authors:  Karim Si-Tayeb; Frédéric P Lemaigre; Stephen A Duncan
Journal:  Dev Cell       Date:  2010-02-16       Impact factor: 12.270

3.  Hepatocyte nuclear factor 4α-nuclear factor-κB feedback circuit modulates liver cancer progression.

Authors:  Bei-Fang Ning; Jin Ding; Jiao Liu; Chuan Yin; Wen-Ping Xu; Wen-Ming Cong; Qing Zhang; Fei Chen; Tao Han; Xing Deng; Pei-Qin Wang; Cai-Feng Jiang; Jun-Ping Zhang; Xin Zhang; Hong-Yang Wang; Wei-Fen Xie
Journal:  Hepatology       Date:  2014-06-27       Impact factor: 17.425

Review 4.  Gene regulatory networks in differentiation and direct reprogramming of hepatic cells.

Authors:  Claude Gérard; Janne Tys; Frédéric P Lemaigre
Journal:  Semin Cell Dev Biol       Date:  2016-12-12       Impact factor: 7.727

Review 5.  Recent advances in the surgical treatment of hepatocellular carcinoma.

Authors:  Zenichi Morise; Norihiko Kawabe; Hirokazu Tomishige; Hidetoshi Nagata; Jin Kawase; Satoshi Arakawa; Rie Yoshida; Masashi Isetani
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

6.  Liver xeno-repopulation with human hepatocytes in Fah-/-Rag2-/- mice after pharmacological immunosuppression.

Authors:  Zhiying He; Haibin Zhang; Xin Zhang; Dongfu Xie; Yixin Chen; Kirk J Wangensteen; Stephen C Ekker; Meri Firpo; Changcheng Liu; Dao Xiang; Xiaoyuan Zi; Lijian Hui; Guangshun Yang; Xiaoyan Ding; Yiping Hu; Xin Wang
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

7.  In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green.

Authors:  Takatsugu Yamada; Masahide Yoshikawa; Seiji Kanda; Yoko Kato; Yoshiyuki Nakajima; Shigeaki Ishizaka; Yukio Tsunoda
Journal:  Stem Cells       Date:  2002       Impact factor: 6.277

8.  Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice.

Authors:  Hisaya Azuma; Nicole Paulk; Aarati Ranade; Craig Dorrell; Muhsen Al-Dhalimy; Ewa Ellis; Stephen Strom; Mark A Kay; Milton Finegold; Markus Grompe
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

9.  Elite model for the generation of induced pluripotent cancer cells (iPCs).

Authors:  Jason Lai; Chiou Mee Kong; Dashayini Mahalingam; Xiaojin Xie; Xueying Wang
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

10.  Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity.

Authors:  Antonis Kourtidis; Siu P Ngok; Pamela Pulimeno; Ryan W Feathers; Lomeli R Carpio; Tiffany R Baker; Jennifer M Carr; Irene K Yan; Sahra Borges; Edith A Perez; Peter Storz; John A Copland; Tushar Patel; E Aubrey Thompson; Sandra Citi; Panos Z Anastasiadis
Journal:  Nat Cell Biol       Date:  2015-08-24       Impact factor: 28.824

View more
  17 in total

1.  Tissue-specific transcription reprogramming promotes liver metastasis of colorectal cancer.

Authors:  Shuaishuai Teng; Yang Eric Li; Zhi John Lu; Dong Wang; Ming Yang; Rui Qi; Yiming Huang; Qianyu Wang; Yanmei Zhang; Shanwen Chen; Shasha Li; Kequan Lin; Yang Cao; Qunsheng Ji; Qingyang Gu; Yujing Cheng; Zai Chang; Wei Guo; Pengyuan Wang; Ivan Garcia-Bassets
Journal:  Cell Res       Date:  2019-12-06       Impact factor: 46.297

Review 2.  Conditional reprogramming: Modeling urological cancer and translation to clinics.

Authors:  Wei Liu; Lingao Ju; Songtao Cheng; Gang Wang; Kaiyu Qian; Xuefeng Liu; Yu Xiao; Xinghuan Wang
Journal:  Clin Transl Med       Date:  2020-06-05

3.  Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.

Authors:  Bai-Nan Zheng; Chen-Hong Ding; Shi-Jie Chen; Kongkai Zhu; Jingwei Shao; Jifeng Feng; Wen-Ping Xu; Ling-Yan Cai; Chang-Peng Zhu; Wenhu Duan; Jin Ding; Xin Zhang; Cheng Luo; Wei-Fen Xie
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

Review 4.  Cancer cell reprogramming: a promising therapy converting malignancy to benignity.

Authors:  Lanqi Gong; Qian Yan; Yu Zhang; Xiaona Fang; Beilei Liu; Xinyuan Guan
Journal:  Cancer Commun (Lond)       Date:  2019-08-29

5.  HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.

Authors:  Yanan Lu; Dongni Xu; Jintao Peng; Zhaofan Luo; Chujie Chen; Yuqing Chen; Huimou Chen; Minghui Zheng; Peihong Yin; Zhi Wang
Journal:  EBioMedicine       Date:  2019-05-15       Impact factor: 8.143

Review 6.  RFX1: a promising therapeutic arsenal against cancer.

Authors:  Joby Issac; Pooja S Raveendran; Ani V Das
Journal:  Cancer Cell Int       Date:  2021-05-08       Impact factor: 5.722

7.  Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification.

Authors:  Lawrence Howell; Rosalind E Jenkins; Stephen Lynch; Carrie Duckworth; B Kevin Park; Christopher Goldring
Journal:  Arch Toxicol       Date:  2021-05-29       Impact factor: 5.153

8.  Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses.

Authors:  Tran N Nguyen; Ha Q Nguyen; Duc-Hau Le
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

9.  Over a century of cancer research: Inconvenient truths and promising leads.

Authors:  Carlos Sonnenschein; Ana M Soto
Journal:  PLoS Biol       Date:  2020-04-01       Impact factor: 9.593

Review 10.  Cell Fate Reprogramming in the Era of Cancer Immunotherapy.

Authors:  Olga Zimmermannova; Inês Caiado; Alexandra G Ferreira; Carlos-Filipe Pereira
Journal:  Front Immunol       Date:  2021-07-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.